Overview
Postmenopausal Estrogen/Progestin Interventions (PEPI)
Status:
Completed
Completed
Trial end date:
2000-10-01
2000-10-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
Treatments:
EstrogensEstrogens, Conjugated (USP)
Medroxyprogesterone
Medroxyprogesterone Acetate
Progesterone